Rozenbaum, Mark H.
Tran, Diana
Bhambri, Rahul
Nativi-Nicolau, Jose
Funding for this research was provided by:
Pfizer Inc.
Article History
Accepted: 18 February 2022
First Online: 30 March 2022
Declarations
:
: This work was financially supported by Pfizer Inc., who also funded the journal’s Open Access fee.
: Mark Rozenbaum and Rahul Bhambri are employees of Pfizer and hold Pfizer stock and/or stock options. Editorial/medical writing support and data analysis were provided by Diana Tran at EVERSANA and was funded by Pfizer Inc. Jose Nativi-Nicolau received funding for clinical trials from Pfizer, Akcea, and Eidos and Educational Grants from Pfizer and has been a consultant for Pfizer, Eidos, Akcea, and Alnylam.
: Not applicable.
: Not applicable.
: Not applicable.
: All data generated or analyzed during this study are included in this article.
: Not applicable.
: All authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article. All authors had full access to the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis. MHR and DT designed the study. DT conducted the analyses and drafted the manuscript. All authors critically reviewed the manuscript for intellectual content and approved the final version of the manuscript.